Repeat customers are now the ones asking for more capacity: management describes buyers it has already served pressing f
The model's full reasoning — Q3 2018 call → NOWe need answer only YES or NO. Need analyze transcript. Need determine if management describes buyers who already bought and seen result are asking for more than company can supply, and company enlarging in response. Need one coherent situation with three elements. Let's parse transcript. Company Precipio, diagnostics, liquid biopsy ICP, pathology services, IV-Cell, HemeScreen. Key parts: - ICP product line expanded. Perkin Elmer partnership: "Perkin Elmer ... selected ICP as DNA enrichment technology ... co-marketing agreement ... first step in building strong ongoing relationship ... both companies committed ... While partnership with Perkin is new in rapidly growing liquid biopsy market, we estimate 2019 revenues between several hundreds to several million dollars resulting from market penetration of ICP within current and future Perkin Elmer and Precipio customers..." This is new partnership, not proven repeat counterparties? Perkin Elmer selected ICP, but not yet revenue? It's a co-marketing agreement, not existing buyers asking for more than supply. No. - Pathology services: "during last quarter we continue to invest in sales force and hired top notch individuals. Our 10-member strong teams in Q3 have contributed to growth in customer base resulting as we've recently announced in our revenues from pathology services growing close to 50% from previous quarter. With substantial pipeline of new customers and strong conversion rates, we expect continued rapid growth... revenues from pathology services alone exceeding $1 million per quarter by middle of 2019." This is new customers, pipeline, not existing buyers asking for more than supply. No. - IV-Cell: "Earlier this year we announced trial with University of Pennsylvania... learned commercialization possible without external academic validation. Interested parties -- partners that connected with us received samples of reagent and were able to test IV-Cell technology in their own laboratory to see it works. So commercialization process proceeded in parallel... We believe we're making great strides..." This is interested parties testing, not necessarily repeat buyers asking for more than supply. No. - HemeScreen: "born from frustrations of existing test used in our CLIA lab...
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ROCK | Gibraltar Industries, Inc. | Q1 2024 | 2024-05-01 | B+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| FSS | Federal Signal Corporation | Q1 2018 | 2018-05-12 | A |
ROCK · Q1 2024 → YESThe question is whether management describes that buyers who have already bought from the company and seen the result are now asking for more than the company can currently supply, and management is w...YES The transcript shows management describing exactly this situation in the renewables segment. Existing customers who previously bought fixed-tilt racking (proven repeat counterparties) have switched to the new 1P TerraTrak tracker technology, creating rapid uptake that exceeds current supply capability.
GIII · Q4 2024 → YESThe question is whether management describes that buyers who have already bought from the company and seen the result are now asking for more than the company can currently supply, and management is w...
PI · Q4 2022 → YESThe question is whether management describes that buyers who have already bought from the company and seen the result are now asking for more than the company can currently supply, and management is w...